# Muscadine Plus (MPX) In Men With Prostate Cancer

> **NCT03535675** · PHASE3 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 59 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Muscadine Plus
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03535675
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-30
- **Primary completion:** 2022-07-06
- **Final completion:** 2022-11-03
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** The study was terminated by DSMB due to futility.
- **Last updated:** 2023-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535675, "Muscadine Plus (MPX) In Men With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03535675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*